Interestingly, for melanoma patients treated with anti-PD1, although there was no significant difference in TMB between responders and non-responders, the count of neoantigens from in-frame insertion mutation was significantly higher in responders (p-value 0.021, Figure 1D), which may be a response signature in anti-PD1 treated melanoma. The gene discussed is PDCD1; the disease is melanoma.